Table S1 from Fibronectin Contributes to a BRAF Inhibitor–driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2

Hicks, Hannah M.; Pozdeyev, Nikita; Sams, Sharon B.; Pugazhenthi, Umarani; Bales, Elise S.; Hofmann, Marie-Claude; McKenna, Logan R.; Schweppe, Rebecca E.

doi:10.1158/1541-7786.23516053.v1

Table S1 from Fibronectin Contributes to a BRAF Inhibitor–driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2

journal contribution

posted on 2023-06-14, 15:20 authored by Hannah M. Hicks, Nikita Pozdeyev, Sharon B. Sams, Umarani Pugazhenthi, Elise S. Bales, Marie-Claude Hofmann, Logan R. McKenna, Rebecca E. Schweppe

Table S1. Thyroid cancer cell lines and their sensitivity/resistance to BRAFi.

History

ARTICLE ABSTRACT

Together, these data show that increased invasion represents a new mechanism of resistance to BRAF inhibition in thyroid cancer that can be targeted with an ERK1/2 inhibitor.